These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30968858)

  • 21. Evaluating naloxegol for the treatment of opioid-induced constipation.
    Daniali M; Nikfar S; Abdollahi M
    Expert Opin Pharmacother; 2020 Jun; 21(8):883-891. PubMed ID: 32129103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioid-induced constipation in chronic noncancer pain.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):11-7. PubMed ID: 26702846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis.
    Cobo Dols M; Beato Zambrano C; Cabezón Gutiérrez L; Chicas Sett R; Blancas López-Barajas MI; García Navalón F; Fírvida Pérez JL; Serrano Bermúdez G; Togores Torres P; Delgado Mingorance I; Giraldo Marín A; Librán Oriol A; Paredes Lario A; Sánchez Mauriño P; Higuera Gómez O; Moreno Muñoz D; Jiménez López AJ; Huerta González I; Sanz Yagüe A; Soler López B
    BMJ Support Palliat Care; 2021 Mar; 11(1):25-31. PubMed ID: 32376758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological characterization of naloxegol: In vitro and in vivo studies.
    Costanzini A; Ruzza C; Neto JA; Sturaro C; Malfacini D; Sternini C; De Giorgio R; Calò G
    Eur J Pharmacol; 2021 Jul; 903():174132. PubMed ID: 33933466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naloxegol increases frequency of bowel movements and combats inadequate response to laxatives.
    Holzer P
    Evid Based Med; 2015 Feb; 20(1):5. PubMed ID: 25209526
    [No Abstract]   [Full Text] [Related]  

  • 27. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain.
    Leonard J; Baker DE
    Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naloxegol versus Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Patients.
    Tobben D; Carpenter S; Kolar R; Merritt T; Young T; Hauser P; Collier T
    Ann Pharmacother; 2024 Jul; 58(7):678-684. PubMed ID: 37881915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
    Gottfridsson C; Carlson G; Lappalainen J; Sostek M
    Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
    Streicher JM; Bilsky EJ
    J Pharm Pract; 2018 Dec; 31(6):658-669. PubMed ID: 28946783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associated mood changes with naloxegol therapy for opioid-induced constipation in a patient with psychiatric disease.
    Nagda N; Javed S
    Pain Manag; 2022 Jan; 12(1):13-16. PubMed ID: 34284647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
    Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
    Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?
    Holzer P
    Curr Pharm Des; 2012; 18(37):6010-20. PubMed ID: 22747544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ▼Naloxegol for opioid-induced constipation.
    Drug Ther Bull; 2015 Dec; 53(12):138-40. PubMed ID: 26660436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation.
    Al-Huniti N; Xu H; Zhou D; Aksenov S; Fox R; Bui KH
    CPT Pharmacometrics Syst Pharmacol; 2017 Oct; 6(10):705-711. PubMed ID: 28782266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation.
    Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M
    CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic Profile of Naloxegol, a Peripherally Acting
    Floettmann E; Bui K; Sostek M; Payza K; Eldon M
    J Pharmacol Exp Ther; 2017 May; 361(2):280-291. PubMed ID: 28336575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
    Webster L; Tummala R; Diva U; Lappalainen J
    J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
    Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
    J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.
    De Giorgio R; Zucco FM; Chiarioni G; Mercadante S; Corazziari ES; Caraceni A; Odetti P; Giusti R; Marinangeli F; Pinto C
    Adv Ther; 2021 Jul; 38(7):3589-3621. PubMed ID: 34086265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.